tiprankstipranks
Trending News
More News >
Rocket Pharmaceuticals (RCKT)
NASDAQ:RCKT
US Market

Rocket Pharmaceuticals (RCKT) Stock Forecast & Price Target

Compare
1,548 Followers
See the Price Targets and Ratings of:

RCKT Analyst Ratings

Moderate Buy
17Ratings
Moderate Buy
9 Buy
7 Hold
1 Sell
Based on 17 analysts giving stock ratings to
Rocket
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

RCKT Stock 12 Month Forecast

Average Price Target

$10.75
▲(288.09%Upside)
Based on 17 Wall Street analysts offering 12 month price targets for Rocket Pharmaceuticals in the last 3 months. The average price target is $10.75 with a high forecast of $30.00 and a low forecast of $2.00. The average price target represents a 288.09% change from the last price of $2.77.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","16":"$16","31":"$31","8.5":"$8.5","23.5":"$23.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,8.5,16,23.5,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.77,4.864615384615385,6.9592307692307696,9.053846153846154,11.148461538461538,13.243076923076922,15.337692307692308,17.432307692307692,19.526923076923076,21.62153846153846,23.716153846153844,25.81076923076923,27.905384615384616,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.77,3.3838461538461537,3.997692307692308,4.611538461538462,5.225384615384616,5.83923076923077,6.453076923076924,7.066923076923077,7.680769230769231,8.294615384615385,8.90846153846154,9.522307692307693,10.136153846153848,{"y":10.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.77,2.710769230769231,2.6515384615384616,2.5923076923076924,2.5330769230769232,2.473846153846154,2.4146153846153844,2.355384615384615,2.296153846153846,2.236923076923077,2.1776923076923076,2.1184615384615384,2.059230769230769,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":21.32,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.66,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.23,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.85,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.12,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.98,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.41,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.57,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.74,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.45,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.81,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.86,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.77,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$30.00Average Price Target$10.75Lowest Price Target$2.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on RCKT
Whitney IjemCanaccord Genuity
Canaccord Genuity
$34$11
Buy
297.11%
Upside
Reiterated
06/03/25
Rocket Pharmaceuticals price target lowered to $11 from $34 at CanaccordRocket Pharmaceuticals price target lowered to $11 from $34 at Canaccord
Evercore ISI
$5
Hold
80.51%
Upside
Downgraded
06/03/25
Rocket Pharmaceuticals (RCKT) was downgraded to a Hold Rating at Evercore ISI
LifeSci Capital Analyst forecast on RCKT
Cory Jubinville, PhDLifeSci Capital
LifeSci Capital
$9
Buy
224.91%
Upside
Reiterated
05/31/25
LifeSci Capital Keeps Their Buy Rating on Rocket Pharmaceuticals (RCKT)
Chardan Capital Analyst forecast on RCKT
Geulah LivshitsChardan Capital
Chardan Capital
$46$17
Buy
513.72%
Upside
Reiterated
05/28/25
Rocket Pharmaceuticals price target lowered to $17 from $46 at ChardanRocket Pharmaceuticals price target lowered to $17 from $46 at Chardan
Bank of America Securities Analyst forecast on RCKT
Jason ZemanskyBank of America Securities
Bank of America Securities
$32$9
Buy
224.91%
Upside
Reiterated
05/28/25
Bank of America Securities Keeps Their Buy Rating on Rocket Pharmaceuticals (RCKT)
J.P. Morgan Analyst forecast on RCKT
Eric JosephJ.P. Morgan
J.P. Morgan
$44$7
Hold
152.71%
Upside
Downgraded
05/28/25
J.P. Morgan downgrades Rocket Pharmaceuticals (RCKT) to a Hold
Jefferies Analyst forecast on RCKT
Andrew TsaiJefferies
Jefferies
$29$2.5
Hold
-9.75%
Downside
Downgraded
05/28/25
Jefferies Sticks to Its Buy Rating for Rocket Pharmaceuticals (RCKT)
Goldman Sachs Analyst forecast on RCKT
Richard Law CFAGoldman Sachs
Goldman Sachs
$2
Sell
-27.80%
Downside
Downgraded
05/28/25
Rocket Pharmaceuticals downgraded to Sell from Neutral at Goldman SachsRocket Pharmaceuticals downgraded to Sell from Neutral at Goldman Sachs
Scotiabank Analyst forecast on RCKT
Greg HarrisonScotiabank
Scotiabank
$51$19
Buy
585.92%
Upside
Reiterated
05/28/25
Rocket Pharmaceuticals (RCKT) Gets a Buy from Scotiabank
Morgan Stanley Analyst forecast on RCKT
Michael UlzMorgan Stanley
Morgan Stanley
$42$7
Hold
152.71%
Upside
Downgraded
05/28/25
Morgan Stanley Sticks to Their Buy Rating for Rocket Pharmaceuticals (RCKT)
Leerink Partners Analyst forecast on RCKT
Mani ForooharLeerink Partners
Leerink Partners
$37$8
Hold
188.81%
Upside
Downgraded
05/28/25
Rocket's Danon update raises specter of worst-case scenario, Leerink saysRocket's Danon update raises specter of worst-case scenario, Leerink says
William Blair Analyst forecast on RCKT
Sami CorwinWilliam Blair
William Blair
Buy
Reiterated
05/27/25
Resilience and Proactive Measures: Rocket Pharmaceuticals' Path to Overcoming Clinical Challenges and Future Success
TD Cowen
Hold
Downgraded
05/27/25
Rocket Pharmaceuticals (RCKT) was downgraded to a Hold Rating at TD Cowen
Needham Analyst forecast on RCKT
Gil BlumNeedham
Needham
Hold
Downgraded
05/27/25
Needham downgrades Rocket Pharmaceuticals (RCKT) to a Hold
Wedbush Analyst forecast on RCKT
Yun ZhongWedbush
Wedbush
$32$16
Buy
477.62%
Upside
Reiterated
05/27/25
Rocket Pharmaceuticals price target lowered to $16 from $32 at WedbushRocket Pharmaceuticals price target lowered to $16 from $32 at Wedbush
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on RCKT
Whitney IjemCanaccord Genuity
Canaccord Genuity
$34$11
Buy
297.11%
Upside
Reiterated
06/03/25
Rocket Pharmaceuticals price target lowered to $11 from $34 at CanaccordRocket Pharmaceuticals price target lowered to $11 from $34 at Canaccord
Evercore ISI
$5
Hold
80.51%
Upside
Downgraded
06/03/25
Rocket Pharmaceuticals (RCKT) was downgraded to a Hold Rating at Evercore ISI
LifeSci Capital Analyst forecast on RCKT
Cory Jubinville, PhDLifeSci Capital
LifeSci Capital
$9
Buy
224.91%
Upside
Reiterated
05/31/25
LifeSci Capital Keeps Their Buy Rating on Rocket Pharmaceuticals (RCKT)
Chardan Capital Analyst forecast on RCKT
Geulah LivshitsChardan Capital
Chardan Capital
$46$17
Buy
513.72%
Upside
Reiterated
05/28/25
Rocket Pharmaceuticals price target lowered to $17 from $46 at ChardanRocket Pharmaceuticals price target lowered to $17 from $46 at Chardan
Bank of America Securities Analyst forecast on RCKT
Jason ZemanskyBank of America Securities
Bank of America Securities
$32$9
Buy
224.91%
Upside
Reiterated
05/28/25
Bank of America Securities Keeps Their Buy Rating on Rocket Pharmaceuticals (RCKT)
J.P. Morgan Analyst forecast on RCKT
Eric JosephJ.P. Morgan
J.P. Morgan
$44$7
Hold
152.71%
Upside
Downgraded
05/28/25
J.P. Morgan downgrades Rocket Pharmaceuticals (RCKT) to a Hold
Jefferies Analyst forecast on RCKT
Andrew TsaiJefferies
Jefferies
$29$2.5
Hold
-9.75%
Downside
Downgraded
05/28/25
Jefferies Sticks to Its Buy Rating for Rocket Pharmaceuticals (RCKT)
Goldman Sachs Analyst forecast on RCKT
Richard Law CFAGoldman Sachs
Goldman Sachs
$2
Sell
-27.80%
Downside
Downgraded
05/28/25
Rocket Pharmaceuticals downgraded to Sell from Neutral at Goldman SachsRocket Pharmaceuticals downgraded to Sell from Neutral at Goldman Sachs
Scotiabank Analyst forecast on RCKT
Greg HarrisonScotiabank
Scotiabank
$51$19
Buy
585.92%
Upside
Reiterated
05/28/25
Rocket Pharmaceuticals (RCKT) Gets a Buy from Scotiabank
Morgan Stanley Analyst forecast on RCKT
Michael UlzMorgan Stanley
Morgan Stanley
$42$7
Hold
152.71%
Upside
Downgraded
05/28/25
Morgan Stanley Sticks to Their Buy Rating for Rocket Pharmaceuticals (RCKT)
Leerink Partners Analyst forecast on RCKT
Mani ForooharLeerink Partners
Leerink Partners
$37$8
Hold
188.81%
Upside
Downgraded
05/28/25
Rocket's Danon update raises specter of worst-case scenario, Leerink saysRocket's Danon update raises specter of worst-case scenario, Leerink says
William Blair Analyst forecast on RCKT
Sami CorwinWilliam Blair
William Blair
Buy
Reiterated
05/27/25
Resilience and Proactive Measures: Rocket Pharmaceuticals' Path to Overcoming Clinical Challenges and Future Success
TD Cowen
Hold
Downgraded
05/27/25
Rocket Pharmaceuticals (RCKT) was downgraded to a Hold Rating at TD Cowen
Needham Analyst forecast on RCKT
Gil BlumNeedham
Needham
Hold
Downgraded
05/27/25
Needham downgrades Rocket Pharmaceuticals (RCKT) to a Hold
Wedbush Analyst forecast on RCKT
Yun ZhongWedbush
Wedbush
$32$16
Buy
477.62%
Upside
Reiterated
05/27/25
Rocket Pharmaceuticals price target lowered to $16 from $32 at WedbushRocket Pharmaceuticals price target lowered to $16 from $32 at Wedbush
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Rocket Pharmaceuticals

1 Month
xxx
Success Rate
14/24 ratings generated profit
58%
Average Return
+5.81%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 58.33% of your transactions generating a profit, with an average return of +5.81% per trade.
3 Months
xxx
Success Rate
14/24 ratings generated profit
58%
Average Return
+14.08%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 58.33% of your transactions generating a profit, with an average return of +14.08% per trade.
1 Year
Geulah LivshitsChardan Capital
Success Rate
14/24 ratings generated profit
58%
Average Return
+20.39%
reiterated a buy rating 10 days ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +20.39% per trade.
2 Years
xxx
Success Rate
3/11 ratings generated profit
27%
Average Return
-35.69%
reiterated a xxx
rating 7 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 27.27% of your transactions generating a profit, with an average return of -35.69% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RCKT Analyst Recommendation Trends

Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
18
17
15
31
29
Buy
2
2
2
5
5
Hold
1
1
1
9
10
Sell
0
0
0
1
1
Strong Sell
0
0
0
0
0
total
21
20
18
46
45
In the current month, RCKT has received 34 Buy Ratings, 10 Hold Ratings, and 1 Sell Ratings. RCKT average Analyst price target in the past 3 months is 10.75.
Each month's total comprises the sum of three months' worth of ratings.

RCKT Financial Forecast

RCKT Earnings Forecast

Next quarter’s earnings estimate for RCKT is -$0.56 with a range of -$0.63 to -$0.50. The previous quarter’s EPS was -$0.56. RCKT beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year RCKT has Outperformed its overall industry.
Next quarter’s earnings estimate for RCKT is -$0.56 with a range of -$0.63 to -$0.50. The previous quarter’s EPS was -$0.56. RCKT beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year RCKT has Outperformed its overall industry.
No data currently available

RCKT Sales Forecast

Next quarter’s sales forecast for RCKT is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. RCKT beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year RCKT has Preformed in-line its overall industry.
Next quarter’s sales forecast for RCKT is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. RCKT beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year RCKT has Preformed in-line its overall industry.

RCKT Stock Forecast FAQ

What is RCKT’s average 12-month price target, according to analysts?
Based on analyst ratings, Rocket Pharmaceuticals’s 12-month average price target is 10.75.
    What is RCKT’s upside potential, based on the analysts’ average price target?
    Rocket Pharmaceuticals has 288.09% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is RCKT a Buy, Sell or Hold?
          Rocket Pharmaceuticals has a consensus rating of Moderate Buy which is based on 9 buy ratings, 7 hold ratings and 1 sell ratings.
            What is Rocket Pharmaceuticals’s price target?
            The average price target for Rocket Pharmaceuticals is 10.75. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $30.00 ,the lowest forecast is $2.00. The average price target represents 288.09% Increase from the current price of $2.77.
              What do analysts say about Rocket Pharmaceuticals?
              Rocket Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 17 Wall Streets Analysts.
                How can I buy shares of RCKT?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis